ACE Report Cover
Bone morphogenetic protein vs. autologous iliac crest bone graft in lumbar fusion surgery
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descargar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descargar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos

SPINE

Bone morphogenetic protein vs. autologous iliac crest bone graft in lumbar fusion surgery .

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2014;2(16):30 PLoS One. 2014 Jun 2;9(6):e97049. doi: 10.1371/journal.pone.0097049. eCollection 2014.

Autores colaboradores

H Zhang F Wang L Ding Z Zhang D Sun X Feng J An Y Zhu

19 randomized controlled trials (n=1852) were included in this meta-analysis comparing bone morphogenetic protein (BMP) to autogenous iliac crest bone graft (ICBG) in lumbar fusion for patients with lumbar degenerative disease. Results demonstrated a significantly higher fusion rate, significantly lower reoperation rate, and a significantly shorter operation time favouring BMP over ICBG. Hospital stay was borderline significant in favour of BMP, while clinical success, complication rate, blood loss, patient satisfaction, work status, return to work were not significantly different between patient cohorts.


Detalles de la financiación de la publicación +
Financiación:
Non-funded
Conflictos:
None disclosed

Riesgo de sesgo

10/10

Criterios de información

19/20

Índice de fragilidad

N/A

Were the search methods used to find evidence (original research) on the primary question or questions stated?

Was the search for evidence reasonably comprehensive?

Were the criteria used for deciding which studies to include in the overview reported?

Was the bias in the selection of studies avoided?

Were the criteria used for assessing the validity of the included studies reported?

Was the validity of all of the studies referred to in the text assessed with use of appropriate criteria (either in selecting the studies for inclusion or in analyzing the studies that were cited)?

Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported?

Were the findings of the relevant studies combined appropriately relative to the primary question that the overview addresses?

Were the conclusions made by the author or authors supported by the data and or analysis reported in the overview?

How would you rate the scientific quality of this evidence?

Sí = 1

Incierto = 0,5

No relevante = 0

No = 0

La evaluación de los criterios de información evalúa la transparencia con la que los autores informan de las características metodológicas y del ensayo dentro de la publicación. La evaluación se divide en cinco categorías que se presentan a continuación.

4/4

Introduction

4/4

Accessing Data

4/4

Analysing Data

4/4

Results

3/4

Discussion

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

El Índice de Fragilidad es una herramienta que ayuda en la interpretación de hallazgos significativos, proporcionando una medida de fuerza para un resultado. El Índice de Fragilidad representa el número de eventos consecutivos que es necesario añadir a un resultado dicotómico para que el hallazgo deje de ser significativo. Un número pequeño representa un hallazgo más débil y un número grande un hallazgo más fuerte.

¿Por qué se necesitaba ahora este estudio?

In lumbar fusion surgery, autogenous iliac crest bone (ICBG) is primarily used as a graft. Nonetheless, well-documented complications have included morbidity of the donor site and a high incidence of nonunion. In light of this, bone morphogenetic proteins (BMPs) have been developed as an alternative. Large scale production was achieved following advancements in gene sequencing and recombinant techniques. Both rhBMP-2 and rhBMP-7 have been approved by the FDA. This meta-analysis was needed to evaluate the comparative efficacy of BMPs to ICBG in spinal fusion surgery.

¿Cuál era la pregunta principal de la investigación?

How does the safety and efficacy of bone morphogenetic proteins compare to autogenous iliac crest bone grafts in lumbar fusion surgery?

Características del estudio +
Fuente de datos:
An electronic search was performed up to November 2013 in PubMed, The Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE and EMBASE, CINAHL, the China Biological Medicine Database (CBM), International Clinical Trials Registry Platform (ICTRP), Current Controlled Trials, and ClinicalTrials.gov. Relevant systematic reviews, RCTs identified from search, meeting abstracts, and expert opinion communications were additionally searched.
Términos del índice:
Key search terms included: 'lumbar degenerative disease', 'low back pain', 'lumbar fusion, 'bone morphogenetic protein-2', 'bone morphogenetic protein-7', 'osteogenic protein-1', and 'randomized controlled trial'.
Selección de estudios:
Randomized controlled trials (RCTs) were included if BMPs were compared to ICBG for the treatment of systematic lumbar degenerative disease (LDD) in adults (>18 years) requiring lumbar fusion. Studies were excluded if included patients had a spinal column fracture, spondylolisthesis (> Meyerding Grade 2), or were taking medication with potential interference of fusion. Two reviewers performed the selection which was then checked by principal reviewer. Disagreements were resolved through discussion. 19 RCTs (15 BMP-2 and 4 BMP-7), totaling 1852 patients were included.
Extracción de datos:
Two independent reviewers extracted data. The primary outcomes extracted included: solid fusion rate, clinical outcomes, compilations, and reoperation rate. The secondary outcomes extracted included: operation time, blood loss, hospital stay, patient satisfaction, and return to work.
Síntesis de datos:
Dichotomous outcomes were measured with risk ratios (RR) and 95% confidence intervals while continuous outcomes were measured with mean differences (MD) and 95% CIs and standardized mean differences (SMDs) as necessary. A random-effects model was used for analysis. Publication bias was assessed with a funnel plot and statistic tests (Egger's test and Begg's test). Heterogeneity was assessed using the chi-square test and I-squared statistic; significant heterogeneity was defined as I-squared >/=50%. RevMan 5.1.0 and R project 3.0.1 was used to analyze data. Clinical relevance was assessed by criteria of the Cochrane Back Review Group. Methodological quality was assessed using criteria by the Cochrane Back Review Group by two independent reviewers, and quality of evidence was assessed with the GRADE Working Group criteria.
¿Cuáles fueron los hallazgos importantes?
  • Fusion rate was reported in 17 studies (BMP: n=610, ICBG: n=523). Pooled analysis indicated a significant difference, in favour of BMP over ICBG, although with moderate heterogeneity (RR: 1.13 [95% CI 1.05-1.23]; p=0.003; I^2=52%). Subgroup analysis of BMP-2 only demonstrated similar results (RR: 1.16 [95% CI 1.06–1.27]; P = 0.001; I^2=62%). The BMP-7 subgroup indicated contrasting results (RR: 0.90 [95% CI 0.69-1.17]; p=0.43; I^2=0%).
  • Clinical success was assessed in 8 studies (BMP: n=431, ICBG: n=265). Pooling of data demonstrated no significant difference between groups (RR: 1.04 [95% CI 0.95-1.13]; p=0.38; I^2=2%).
  • Complication rate was pooled from 9 studies (BMP: n=605, ICBG: n=444) and results indicated no significant between group difference (RR: 0.96 [95% CI 0.85-1.09]; p=0.54; I^2=0%).
  • Reoperation rate from 14 studies were pooled for analysis (BMP:n=1004, ICBG: n=766). Results demonstrated a significantly lower rate for BMP over ICBG (RR: 0.57 [95% CI 0.42-0.77]; p=0.0002; I^2=0.66).
  • Pooled results favoured BMP over ICBG significantly, with respect to operating time (RR: -0.32 [95% CI -0.55 to -0.08]; p=0.009; I^2=79%), and hospital stay (RR: -0.56 [95% CI -1.12 to -0.01]; p=0.05; I^2=70%), whereas comparable results were observed for blood loss (RR: -50.24 [95% CI -117.38 to 16.90]; p=0.14; I^2=77%).
  • Patient satisfaction, work status, and return to work were not significantly different between groups (p=0.58, p=0.63, and p=0.68, respectively) when pooled.
¿Qué es lo que más debo recordar?

Pooled analyses demonstrated significantly higher fusion rates, lower reoperation rates, and shorter operation times with bone morphogenetic protein (BMP) when compared to autogenous iliac crest bone graft. Additionally, difference in hospital stay was borderline significant in favour of BMP, whereas clinical success, complication rate, blood loss, patient satisfaction, work status, return to work were comparable between groups.

¿Cómo afectará esto al cuidado de mis pacientes?

The results suggest that bone morphogenetic protein increases fusion rate while reducing reoperation rates and operation times for lumbar fusion in patients with systematic lumbar degenerative disease. Clinical success and complication rates, however, were similar to those of the standard autogenous iliac crest bone grafting procedure. Additional high-quality randomized controlled trials are needed to determine the long-term effects of bone morphogenetic protein, and whether it is superior to autogenous iliac crest bone grafting.

DESCARGO DE RESPONSABILIDAD

El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.

0 de 4 artículos mensuales GRATIS desbloqueados
Ha alcanzado su límite de vistas de 4 artículos gratuitos este mes

Acceda a OrtoEvidencia por tan sólo 1,99 $ a la semana.

Manténgase conectado con las últimas pruebas. Cancele en cualquier momento.
  • Valoraciones críticas de los últimos ensayos controlados aleatorizados de gran impacto y revisiones sistemáticas en ortopedia
  • Acceso al contenido del podcast OrthoEvidence, que incluye colaboraciones con el Journal of Bone and Joint Surgery, entrevistas con cirujanos reconocidos internacionalmente y mesas redondas sobre noticias y temas ortopédicos
  • Suscripción a The Pulse, un boletín quincenal basado en la evidencia y diseñado para ayudarle a tomar mejores decisiones clínicas
Upgrade
Close Dialog
Bienvenido
¿Ha olvidado su contraseña?
Comience hoy mismo su prueba GRATUITA

Su cuenta estará afiliada a
e incluye acceso gratuito a OrthoEvidence


O
¿Olvidó su contraseña?

O
Compruebe su correo electrónico

Si existe una cuenta con la dirección de correo electrónico proporcionada, se le enviará un correo electrónico para restablecer la contraseña. Si no ve el correo electrónico, compruebe su carpeta de correo no deseado o spam.

Si necesita más ayuda póngase en contacto con nuestro equipo de asistencia.

Inicie sesión para activar esta función

Para acceder a esta función, debe iniciar sesión en una cuenta activa de OrthoEvidence. Por favor, inicie sesión o cree una cuenta de prueba GRATUITA.

Traducir Informe ACE

OrthoEvidence utiliza un servicio de traducción de terceros para que el contenido sea accesible en varios idiomas. Tenga en cuenta que, aunque se hace todo lo posible para garantizar la exactitud, las traducciones no siempre son perfectas.

Cómo citar esto ACE Report

OrthoEvidence. Bone morphogenetic protein vs. autologous iliac crest bone graft in lumbar fusion surgery. OE Journal. 2014;2(16):30. Available from: https://myorthoevidence.com/AceReport/Show/bone-morphogenetic-protein-vs-autologous-iliac-crest-bone-graft-in-lumbar-fusion-surgery

Copiar cita
Inicie sesión para activar esta función

Para acceder a esta función, debe iniciar sesión en una cuenta activa de OrthoEvidence. Por favor, inicie sesión o cree una cuenta de prueba GRATUITA.

Función de miembro Premium

Para acceder a esta función, debe iniciar sesión en una cuenta Premium de OrthoEvidence.

Compartir ACE Report